FLI1 and systemic sclerosis: Drugs targeting FLI-1 in ECs mainly include YK-4–279, an FLI-1 inhibitor used to treat diseases such as premature retinopathy and diabetic retinopathy by inhibiting FLI-1 transcription in ECs and reducing angiogenesis [90]; camptothecin, an FLI-1 inhibitor used to treat LN by inhibiting FLI-1 translation in ECs and reducing inflammatory factors in the kidney [91]; and cyclophosphamide, an FLI-1 agonist used to treat SSc by normalizing angiogenesis by promoting FLI-1 transcription in ECs [92].